Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | GPR183 | P32249 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10263815 | 0.84 | PIK3CD (0.52) | PIK3CDCYP1A2TDP1KMT2AKDM4E | |
| SCHEMBL11573468 | 0.81 | — | — | |
| SCHEMBL19630484 | 0.81 | KDM4E (0.38) | KMT2AKDM4EPARP1TSHRMCL1 | |
| SCHEMBL20160374 | 0.79 | ROCK2 (0.35) | KDM4EPARP1GPR183HRH3TSHR | |
| SCHEMBL4724080 | 0.78 | PIK3CD (0.50) | PIK3CDCYP1A2TDP1KMT2AKDM4E | |
| SCHEMBL20926962 | 0.78 | KDM4E (0.40) | KDM4EALDH1A1PARP1HRH3 | |
| SCHEMBL18713080 | 0.76 | NAMPT (0.45) | KDM4EALDH1A1PARP1HRH3 | |
| SCHEMBL20349534 | 0.76 | USP2 (0.46) | KMT2AUSP2ALDH1A1SMN1; SMN2HRH3 | |
| SCHEMBL19801208 | 0.75 | PIK3CD (0.44) | PIK3CDCYP1A2TDP1KMT2AKDM4E | |
| SCHEMBL20796436 | 0.74 | KDM4E (0.35) | KMT2AKDM4EALDH1A1TSHRMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022253283-A1 | PROTEIN KINASE DEGRADANT AND USE THEREOF | 中国科学院上海有机化学研究所 | 2022-12-08 | — | — | WO | disclosed |
| US-11179399-B2 | 6-heterocyclyl-4-morpholin-4-ylpyridine-2-one compounds useful for the treatment of cancer and diabetes | SPRINT BIOSCIENCE AB (SE) | 2021-11-23 | — | — | US | disclosed |
| US-20210161906-A1 | 6-HETEROCYCLYL-4-MORPHOLIN-4-YLPYRIDINE-2-ONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES | SPRINT BIOSCIENCE AB (SE) | 2021-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210161906-A1 | 6-HETEROCYCLYL-4-MORPHOLIN-4-YLPYRIDINE-2-ONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES | CDK6, IL6, CDK4 | PIK3CD 2235/4885CYP1A2 886/4885TDP1 913/4885 |
| US-11179399-B2 | 6-heterocyclyl-4-morpholin-4-ylpyridine-2-one compounds useful for the treatment of cancer and diabetes | CDK6, IL6, CDK4 | PIK3CD 2235/4885CYP1A2 886/4885TDP1 913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.